SS-31 (Elamipretide)safety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for SS-31 (Elamipretide) as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. SS-31 (Elamipretide) is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

SS-31 (elamipretide) has one of the largest clinical-trial safety datasets of any compound on this site outside the licensed pharmaceuticals, accumulated through the Stealth BioTherapeutics clinical programme spanning multiple Phase II and Phase III trials. The reported adverse-event profile is favourable: mild-to-moderate injection-site reactions (erythema, transient nodules, occasional pain) are the most common; occasional mild headache, nausea, or fatigue; rare reports of hypersensitivity events. No clinically significant changes in routine haematology, biochemistry, or vital signs have been documented at therapeutic doses in the Phase III trial data. The favourable safety profile is consistent with the mechanism — SS-31's cardiolipin-binding action is a structural stabilisation effect on mitochondrial membranes without engagement of conventional receptors or signalling cascades that would typically produce off-target pharmacology. The tetrapeptide's small size limits immunogenicity risk; anti-drug antibodies have not been a significant issue in the clinical trials. Theoretical safety considerations centre on the chronic-dosing pharmacology of sustained cardiolipin binding. Because cardiolipin is essential to normal mitochondrial function, complete or excessive stabilisation could theoretically impair normal mitochondrial dynamics (fission-fusion cycles, mitochondrial biogenesis in response to demand). The pre-clinical and clinical data have not surfaced signals consistent with this theoretical concern, but chronic dosing pharmacology is incompletely characterised beyond the Phase III trial durations. Specific patient populations may have different risk profiles. Primary mitochondrial disease patients may have altered basal mitochondrial function that affects SS-31 pharmacology in ways not fully characterised. Elderly subjects with heart failure or renal disease may have altered pharmacokinetics. No serious drug-related adverse events have been documented at standard therapeutic doses across the Phase III trial programme. The compound's safety profile has been consistently favourable across the varying clinical-trial contexts.

UK regulatory status

SS-31 (elamipretide) is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. Multiple Phase II and Phase III trials have been conducted but none has yet supported regulatory approval, largely due to primary-endpoint failures in the pivotal trials. It is not a controlled substance under the Misuse of Drugs Act 1971. Research-grade material is available from research-chemical suppliers for legitimate pre-clinical and academic research use; possession for bona fide laboratory research is generally unrestricted in the UK. Supply or administration of SS-31 to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. UK access to elamipretide through Stealth BioTherapeutics clinical trials may be available through UK trial sites participating in ongoing Phase III programmes (particularly Barth syndrome and dry AMD contexts). Individual compassionate-use access has been arranged in select Barth syndrome contexts internationally; UK compassionate use is theoretically possible through the specials framework. SS-31 is not currently on the WADA Prohibited List. Its cardiolipin-targeting mechanism does not fall within any current WADA category, though athletes should verify the current annual Prohibited List. For animal research under ASPA, SS-31 work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. SS-31 (Elamipretide) is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full SS-31 (Elamipretide) research context including mechanism, study citations, and references, see the main SS-31 (Elamipretide) research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.